使用封堵器装置血管内治疗腹主动脉-腔静脉瘘:病例报告与系统文献综述
报告1例腹主动脉瘤破裂继发腹主动脉-腔静脉瘘(ACF)患者,在腹主动脉-双髂动脉覆膜支架置入后使用7 mm Amplatzer房间隔封堵器经皮封堵瘘口,术后6个月影像确认瘘口封闭。系统综述纳入10例患者(含本例),技术成功率100%,术后并发症2/10,3/10需30天内再干预。
要点
- 封堵器装置可用于腹主动脉-腔静脉瘘的血管内封堵,技术成功率100%(10/10)。
- 创伤性ACF可考虑封堵器作为首选治疗;腹主动脉瘤破裂后须置入覆膜支架。
- 术后并发症2/10(血管封堵器移位、髂深静脉血栓),3/10需30天内再干预。
核心结论
- 尽管文献中可用的患者数量稀少,将封堵器装置置入腹主动脉-腔静脉瘘是可行的。
- 对于创伤性ACF,可提出封堵器装置置入作为主要治疗;而在腹主动脉瘤破裂后,覆膜支架置入是必须的。
研究设计与样本
- 病例报告:1例66岁男性腹主动脉瘤破裂继发ACF,急诊置入腹主动脉-双髂动脉覆膜支架,3个月后因瘘持续和囊腔再灌注(II型内漏)经皮置入7 mm Amplatzer房间隔封堵器并辅助栓塞瘤囊。
- 系统文献综述:按PRISMA声明进行(PROSPERO注册号CRD42024512167),检索封堵器装置治疗ACF的文献,纳入10篇出版物共10例患者(含本例),男性100%,年龄范围24-74岁。
主要发现
- ACF病因:创伤后6例、腹主动脉瘤破裂后4例。
- 封堵器置入作为主要手术6/10例,作为二次干预4/10例。
- 使用封堵器类型:血管封堵器4/10、房间隔封堵器3/10、动脉导管封堵器2/10、室间隔封堵器1/10。
- 技术成功率100%,无术中并发症;术后并发症2/10(血管封堵器移位和髂深静脉血栓)。
- 3/10例因ACF持续通畅在30天内需再干预(1例腹主动脉瘤血管内修复、1例弹簧圈再栓塞瘘、1例辅助房间隔封堵器及髂腰动脉栓塞)。
关键数值与推荐
- 随访1-80个月,8/10例无残留动静脉交通。
- 3例腹主动脉瘤患者中,3/3例出现动脉瘤缩小,其中1例存在II型内漏。
临床怎么用
- 作者认为,对于无动脉瘤的创伤后ACF,可提出封堵器装置置入作为首选方法。
- 作者认为,在腹主动脉瘤破裂经覆膜支架治疗的情况下,应考虑封堵器置入处理下腔静脉来源的持续性内漏。
局限性
- 文献中可用的患者数量稀少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aortocaval fistula (ACF) is a life-threatening condition secondary to abdominal aortic aneurysms (AAA) rupture or previous trauma/intervention. The treatment of ACF by an occluder device deployment is a rare but increasingly common approach. We report a case of ACF secondary to ruptured AAA treated with an occluder device after endograft deployment. A 66-year-old male was treated in an emergent setting for a ruptured AAA with ACF deploying aorto-bi-iliac endograft. At 3-month computed tomography angiography (CTA), the persistence of aorto-caval communication and the increased sac reperfusion (type II endoleak) from the lumbar and inferior mesenteric artery were detected. Under local anesthesia and through percutaneous left brachial arterial access and percutaneous right femoral venous access, a 7-mm Amplatzer Septal Occluder was deployed with the "left" atrial end in the aneurysmal sac and the "right" atrial end in the inferior vena cava. The adjunctive embolization of the aneurysmal sac was performed. The post-procedural CTA and 6-month contrast-enhanced ultrasound confirmed the disappearance of endoleak and the exclusion of ACF. A systematic review of the literature according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement was conducted regarding the use of occluder devices to treat ACF (PROSPERO; CRD42024512167). Including the current case, 10 patients (male 100%; age range 24-74 years) in 10 publications were found. ACF after trauma and after AAA rupture was described in 6 and 4 patients, respectively. Occluder device deployment was a primary procedure in 6/10 cases and a secondary intervention in 4/10 cases. Different types of occluder devices (vascular 4/10, atrial septal 3/10, duct 2/10, ventricular septal 1/10) were used. Technical success was 100%, with no intraoperative complications. Postoperative complications occurred in 2/10 patients (vascular plug migration and iliac deep vein thrombosis). Three out 10 patients required reintervention within 30 days for persistent patency of ACF (1 endovascular abdominal aneurysm repair, 1 re-embolization of fistula with coils, 1 patient underwent adjunctive septal occluder device and iliolumbar embolization). In 8/10 patients (length of follow-up: 1-80 months), no residual arterio-venous communication. In 3 patients with AAA, aneurysm shrinkage occurred in 3/3 patients, with type II endoleak in 1 case. Although a scarce number of patients are available in the literature, occluder device deployment into abdominal arterio-venous fistula is feasible. For a traumatic ACF, the occluder device deployment could be proposed as the primary treatment, while, after a ruptured AAA, endograft deployment is mandatory.Clinical ImpactThe use of occluder device for the occlusion of an aorto-caval fistula (ACF) is an off-label technique reported in literature. The technical success mainly depends from the type of deployed occluder device. This treatment should be proposed as first approach in post-traumatic ACF without aneurysms; in case of aneurysmal rupture treated with endograft, the occluder device placement should be considered for persistent endoleak from inferior vena cava.
引用
- Bianchini Massoni C, Pauletti L, Andreone A, et al. Endovascular Treatment of Abdominal Aorto-Caval Fistula With Occluder Devices: Case Report and Systematic Literature Review. J Endovasc Ther. 2025. PMID: 40116334. doi:10.1177/15266028251324801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。